Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.52 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 2/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.41 |
| ▸ | TUBB | P07437 | 4/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.41 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.41 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.41 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.41 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.41 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29644544 | 1.00 | ENPP2 (0.52) | ENPP2TRPV4MEN1KMT2AERN1 | |
| Ethylene Glycol SCHEMBL28089477 | 0.93 | ENPP2 (0.46) | ENPP2TRPV4MEN1KMT2AERN1 | |
| SCHEMBL19204646 | 0.88 | TRPV4 (0.44) | ENPP2TRPV4MEN1KMT2AERN1 | |
| SCHEMBL322537 | 0.83 | ENPP2 (0.52) | ENPP2TRPV4MEN1KMT2AERN1 | |
| SCHEMBL25308686 | 0.80 | ENPP2 (0.41) | ENPP2TTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20704942 | 0.80 | ENPP2 (0.44) | ENPP2TRPV4MEN1KMT2ASLC6A2 | |
| SCHEMBL29447064 | 0.80 | ENPP2 (0.44) | ENPP2TRPV4MEN1KMT2ASLC6A2 | |
| SCHEMBL29952519 | 0.79 | TSHR (0.49) | ENPP2MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL1686371 | 0.79 | TSHR (0.49) | ENPP2MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL15330282 | 0.78 | PLAU (0.44) | ENPP2LMNAFLT1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 488 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114763340-A | Organic compound, application and preparation method thereof, and organic electroluminescent device using organic compound | 北京鼎材科技有限公司 | 2022-07-19 | — | — | CN | claimed |
| US-20260150574-A1 | COMPOSITION FOR ORGANIC OPTOELECTRONIC DIODE, ORGANIC OPTOELECTRONIC DIODE, AND DISPLAY DEVICE | SAMSUNG SDI CO., LTD. (KR) | 2026-05-28 | — | — | US | disclosed |
| US-12583843-B2 | Organic light-emitting device, method for manufacturing same, and composition for organic material layer of organic light-emitting device | LT MATERIALS CO., LTD. (KR) | 2026-03-24 | — | — | US | disclosed |
| US-12534464-B2 | Heterocyclic compound and organic light emitting element comprising same | LT MATERIALS CO., LTD. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-12507589-B2 | Organic light emitting device | LG CHEM, LTD. (KR) | 2025-12-23 | — | — | US | disclosed |
| US-12492191-B2 | Organic light emitting device | LG CHEM, LTD. (KR) | 2025-12-09 | — | — | US | disclosed |
| US-20250340563-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | TAKEDA DEVELOPMENT CENTER AMERICAS, INC. | 2025-11-06 | — | — | US | disclosed |
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-10-30 | — | — | US | disclosed |
| US-12453283-B2 | Compound and organic light emitting device comprising the same | LG CHEM, LTD. (KR) | 2025-10-21 | — | — | US | disclosed |
| US-12402529-B2 | Organic compound, composition, organic optoelectronic device, and display device | SAMSUNG SDI CO., LTD. (KR) | 2025-08-26 | — | — | US | disclosed |
| US-7345058-B2 | (1-Methyl-5-phenyl-1H-pyrazol-4-yl)-(trans-octahydro-isoquinolin-2-yl)methanone; 11 beta -hydroxysteroid dehydrogenase inhibitor; upregulation of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase); antidiabetic agent; type II diabetes mellitus and metabolic syndrome | HOFFMANN-LA ROCHE INC. (US) | 2008-03-18 | — | — | US | disclosed |
| WO-2007134862-A1 | SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS | BAYER HEALTHCARE AG (DE) | 2007-11-29 | — | — | WO | disclosed |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GILLESPIE PAUL | 2007-07-19 | — | — | US | disclosed |
| WO-2007039467-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME (UK) LTD. (GB) | 2007-04-12 | — | — | WO | disclosed |
| US-20060223852-A1 | Pyrazoles | GILLESPIE PAUL | 2006-10-05 | — | — | US | disclosed |
| EP-1638578-A2 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | Anacor Pharmaceuticals, Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005013892-A9 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | ANACOR PHARMACEUTICALS INC (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050054644-A1 | Hydrolytically-resistant boron-containing therapeutics and methods of use | ANACOR PHARMACEUTICALS, LLC | 2005-03-10 | — | — | US | disclosed |
| WO-2005013892-A2 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | ANACOR PHARMACEUTICALS, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20030229067-A1 | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229067-A1 | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use | ADORA2B, OXER1, CNR1 | ENPP2 2202/4885TRPV4 812/4885MEN1 4584/4885 |
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SCNN1B, SCN1B, SCN2B | ENPP2 1629/4885TRPV4 119/4885MEN1 1568/4885 |
| US-20060223852-A1 | Pyrazoles | GPR119, PDK2, PC | ENPP2 2749/4885TRPV4 3513/4885MEN1 1522/4885 |
| US-12453283-B2 | Compound and organic light emitting device comprising the same | CRY1, CYP1A1, CHRM1 | ENPP2 2171/4885TRPV4 1178/4885MEN1 788/4885 |
| US-12534464-B2 | Heterocyclic compound and organic light emitting element comprising same | NR2E3, CDYL, CRY2 | ENPP2 4444/4885TRPV4 3136/4885MEN1 1912/4885 |
| US-20250340563-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | NLRP3, NLRP1, NOD1 | ENPP2 2293/4885TRPV4 2224/4885MEN1 3679/4885 |
| US-12583843-B2 | Organic light-emitting device, method for manufacturing same, and composition for organic material layer of organic light-emitting device | OXER1, RPL22, POR | ENPP2 2057/4885TRPV4 2245/4885MEN1 2123/4885 |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GOT2, PC, CYP11B2 | ENPP2 4168/4885TRPV4 2551/4885MEN1 702/4885 |
| US-12402529-B2 | Organic compound, composition, organic optoelectronic device, and display device | OCIAD1, OXER1, OR10J3 | ENPP2 3258/4885TRPV4 80/4885MEN1 1263/4885 |
| US-20050054644-A1 | Hydrolytically-resistant boron-containing therapeutics and methods of use | BTD, GAA, GBA3 | ENPP2 646/4885TRPV4 4716/4885MEN1 1241/4885 |
| US-12492191-B2 | Organic light emitting device | CYP1A1, ARNT, AOC3 | ENPP2 2984/4885TRPV4 1347/4885MEN1 2411/4885 |
| US-20260150574-A1 | COMPOSITION FOR ORGANIC OPTOELECTRONIC DIODE, ORGANIC OPTOELECTRONIC DIODE, AND DISPLAY DEVICE | OXER1, OR10J3, OPRD1 | ENPP2 3782/4885TRPV4 859/4885MEN1 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.